-
2 months ago | 
biopharminternational.com | Chris Spivey |Philip R. Dormitzer |Phil Felgner |Jeffrey B. Ulmer |Andy Geall
The pivotal paper series brings to a wider audience a sharp focus on important advances in the biomedical field. This particular paper comes at a troubling time in the vaccine industry, which is currently beset by misinformation and disinformation.
-
Feb 21, 2025 | 
biopharminternational.com | Chris Spivey
With a focus on improving drug delivery, David Fairen-Jimenez, PhD, and his company, Vector Bioscience Cambridge, have carved out their corner of precision medicine with their platform that utilizes high-porosity nanomaterials to deliver targeted treatments with less toxicity.
-
Feb 13, 2025 | 
biopharminternational.com | Chris Spivey
Although most common uses for AI revolve around time savings, when it comes to clinical trials, that likely won’t be the case. Instead, AI will play a key role in helping drive up the success rates of these trials—arguably the more critical endpoint. During a panel discussion at the recent Precision Medicine World Conference, William K.
-
Feb 10, 2025 | 
biopharminternational.com | Chris Spivey
In an interview with BioPharm International, Eswar Iyer, MS, PhD, CEO and co-founder of Aikium Inc., elegantly described the elephant in the room for proteomics: why protein predictions often fail despite the huge strides made in harnessing the power of AI for drug discovery.
-
Feb 6, 2025 | 
biopharminternational.com | Chris Spivey
Leroy (Lee) Hood, MD, PhD, has developed a long list of paradigm-shifting scientific instruments that have made possible major advances in the biological and medical sciences. We had a chance to speak with Hood at the Precision Medicine World Conference in Santa Clara, CA, where he discussed the practicalities of turning a disease care system into a health maintenance system and also his plans to develop a new peptide information-based pharmaceutical company.
-
Jan 16, 2025 | 
biopharminternational.com | Chris Spivey
Behind the Headlines is a bi-weekly panel discussion examining the latest trends, readouts, and other factors that drive pharmaceutical news and innovation. Each episode features consultants, venture capitalists, scientists, patient advocates, and journalists discussing the prior weeks’ top news while seeking to highlight the more enduring lessons that hide behind the headlines.
-
Dec 3, 2024 | 
biopharminternational.com | Chris Spivey |Peter Marks |Fouad Atouf |Kenneth C. Chien |Constanze Blume
December 2, 2024By Standardization leading to CGT therapies becoming a standard of care. Importance to outcomes of high-quality starting materials, to reducing batch-to-batch quality, and the possibilities of allogeneic chimeric antigen receptor therapy (CAR-T) successes.
-
Nov 14, 2024 | 
pharmtech.com | Chris Spivey
Behind the Headlines is a bi-weekly panel discussion examining the latesttrends, readouts, and other factors that drive pharmaceutical news and innovation.Each episode features consultants, venture capitalists, scientists, patient advocates, and journalists discussing the prior weeks' top news while seekingto highlight the more enduring lessons that hide behind the headlines.
-
Oct 30, 2024 | 
biopharminternational.com | Chris Spivey
Editor's note: this interview was originally published on PharmTech.com. Frontage Laboratories founder Song Li, PhD, currently the executive chairman, board of directors, at the company, first set up a testing laboratory in Thorofare, NJ, with a focus on analytical and bioanalytical testing that quickly established a reputation for expertise.
-
Oct 29, 2024 | 
pharmtech.com | Chris Spivey
Contract development and manufacturing organization (CDMO) Frontage Laboratories founder Song Li, PhD, who currently holds the position of executive chairman, board of directors, at the company, first set up a testing laboratory in Thorofare, NJ, with a focus on analytical and bioanalytical testing that quickly established a reputation for expertise.
